American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
INTERPACE BIOSCIENCES, INC.
$1.68
+0.60%
OTC: IDXG · 15-min delayed
$38.7MRevenue · FY2025
$24.6MNet income
IDXGOTC
About INTERPACE BIOSCIENCES, INC.
INTERPACE BIOSCIENCES INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2025
- $38.7M
- Net income
- $24.6M
- Total assets
- $33.8M
- Gross margin
- 33.1%
- Operating margin
- -80.5%
- Net margin
- -81.6%
Source: SEC EDGAR · updated Jun 7, 2026
Multi-year
Revenue & profit trend
FY2016
FY2017
FY2018
FY2019
FY2020
Revenue Net income
FY 2020
Financial statements
Income statement
- Revenue
- $32.4M
- Cost of revenue
- $21.7M
- Gross profit
- $10.7M
- Operating expenses
- $36.8M
- Operating income
- -$26.1M
- Income tax
- $53.0K
- Net income
- -$26.5M
Balance sheet
- Total assets
- $45.7M
- Current assets
- $14.1M
- Total liabilities
- $28.2M
- Current liabilities
- $18.2M
- Shareholders’ equity
- -$29.1M
Cash flow
- Operating cash flow
- -$14.0M
- Investing cash flow
- -$1.6M
- Financing cash flow
- $16.6M
- Net cash flow
- $1.1M
Statements via Polygon.io (SEC filings)
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $24.6M in FY2025.
- Revenue grew 148% from FY2016 to FY2020.
- Gross margin of 33.1%, net margin -81.6%.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review INTERPACE BIOSCIENCES, INC..
Write a review
Newsroom
News about INTERPACE BIOSCIENCES, INC.
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
News & sentiment via Polygon.io
Explore
Browse all →
